Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration
Ophthalmology Science · 2025-03 · 5 (2) · 100657
DOI: 10.1016/j.xops.2024.100657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Science, 2025-03. Verfasst von Ryan L Crass und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacometrics, A2-Ai, Ann Arbor, Michigan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Apellis Pharmaceuticals.
Abstract (Originalsprache)
Objective
To develop a population pharmacokinetic (PK) model to characterize serum pegcetacoplan concentration-time data after intravitreal administration in patients with geographic atrophy (GA) or neovascular age-related macular degeneration (nAMD).
Design
Pharmacokinetic modeling.
Participants
Two hundred sixty-one patients with GA or nAMD enrolled in 4 clinical studies of pegcetacoplan.
Methods
Serum concentration data were pooled from 4 clinical studies. Pegcetacoplan dosing included single intravitreal injections of 4, 10, and 20 mg and multiple intravitreal injections of 15 mg monthly or every other month. Considering a high proportion of samples were below the limit of quantification (BLQ) in serum following intravitreal administration, the M3 method of likelihood-based handling of data BLQ was employed in NONMEM (version 7.4). Covariate model development was performed using stepwise forward (α = 0.05) and backward (α = 0.001) selection. Predicted PK parameters and exposure metrics were generated via simulation in serum and vitreous humor. Main Outcome Measures: Pharmacokinetic parameters.
Results
Intravitreal pegcetacoplan displayed absorption-limited (i.e., "flip-flop") kinetics with median empirical Bayes estimated pegcetacoplan absorption and elimination half-lives of 13.1 days and 4.51 days, respectively. Vitreous exposure was predicted to be >1300-fold higher than serum exposure, with maximum concentrations in serum below the threshold required to elicit systemic pharmacodynamic effects. Drug accumulation from first dose to steady state was predicted to be minimal in serum (mean accumulation ratio = 1.50 with monthly dosing, 1.10 with every-other-month dosing) and vitreous humor (mean accumulation ratio = 1.30 with monthly dosing, 1.10 with every-other-month dosing). Age, sex, and baseline C3 level were identified as significant (P < 0.001) predictors of apparent serum pegcetacoplan clearance after intravitreal administration; however, none of the covariate effects appeared to be clinically meaningful given the low absolute maximum serum concentrations achieved (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacometrics, A2-Ai, Ann Arbor, Michigan.
- Clinical Pharmacology, Apellis Pharmaceuticals, Waltham, Massachusetts.
- Clinical Development, Apellis Pharmaceuticals, Waltham, Massachusetts.
- Medical Affairs, Apellis Pharmaceuticals, Waltham, Massachusetts.
- A2-Ai, Ann Arbor, Michigan.
Förderung
- Apellis Pharmaceuticals
Zitieren
APA
Crass, R. L., Prem, K., Gauderault, F., Ribeiro, R., Baumal, C. R., Smith, B., Epling, D., & Chapel, S. (2025). Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration. Ophthalmology Science, 5(2), 100657. https://doi.org/10.1016/j.xops.2024.100657
Vancouver
Crass RL, Prem K, Gauderault F, Ribeiro R, Baumal CR, Smith B, et al. Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration. Ophthalmology Science. 2025;5(2):100657. doi:10.1016/j.xops.2024.100657
BibTeX
@article{Crass2025,
author = {Crass, Ryan L and Prem, Komal and Gauderault, Francois and Ribeiro, Ramiro and Baumal, Caroline R and Smith, Brandon and Epling, Daniel and Chapel, Sunny},
title = {Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration},
journal = {Ophthalmology Science},
year = {2025},
volume = {5},
number = {2},
pages = {100657},
doi = {10.1016/j.xops.2024.100657}
}
EUVIMED